Skip to main content

Table 2 Cardiac diagnostics, therapies and survival data after propensity score matching

From: Statin therapy is associated with improved survival in patients with ventricular tachyarrhythmias

Characteristic

No statin

(n = 212; 50%)

statin

(n = 212; 50%)

p value

Left ventricular ejection function, n (%)

 LVEF ≥55%

63

(30)

60

(28)

0.352

 LVEF 54–35%

63

(30)

62

(29)

 LVEF < 35%

86

(41)

90

(43)

Cardiac therapies at index, n (%)

 Cardiopulmonary resuscitation

61

(29)

51

(24)

0.271

  In hospital

26

(12)

21

(10)

0.439

  Out of hospital

35

(17)

30

(14)

0.500

 External defibrillation

59

(28)

51

(24)

0.375

 External cardioversion

13

(6)

9

(4)

0.381

 Systemic thrombolysis

7

(3)

5

(2)

0.558

 Targeted temperature management (TTM)

5

(2)

8

(4)

0.398

Coronary artery disease, n (%)

 Coronary angiography, overall

131

(62)

140

(66)

0.363

 Coronary artery disease, n (%)

  No evidence of CAD

47

(36)

41

(29)

0.425

  1-vessel

24

(18)

33

(24)

  2-vessel

27

(21)

24

(17)

  3-vessel

33

(25)

42

(30)

 CTO

32

(24)

27

(19)

0.305

 Presence of CABG

15

(12)

30

(21)

0.027

 Intracoronary thrombus

2

(2)

6

(4)

0.180

 CPR during coronary angiography

4

(3)

3

(2)

0.715

PCI, n (%)

28

(21)

43

(31)

0.081

Target lesions

 RCA

11

(5)

16

(8)

0.320

 LMT

1

(0.5)

0

(0)

1.000

 LAD

15

(7)

18

(9)

0.587

 RIM

0

(0)

0

(0)

 LCX

6

(3)

12

(6)

0.148

 Bypass graft

0

(0)

3

(1)

0.248

Electrical therapies at index, n (%)

 Electrophysiological examination

72

(34)

88

(42)

0.109

 Catheter ablation

18

(9)

19

(9)

0.863

Newly implanted devices at index, n (%)

 ICD

54

(26)

54

(26)

1.000

 CRT-D

3

(1)

8

(4)

0.127

 CRT-P

1

(0.5)

0

(0)

1.000

 Pacemaker

4

(2)

2

(0.9)

0.685

 Cardiac contractility modulation (CCM)

0

(0)

0

(0)

 Subcutaneous ICD

0

(0)

1

(0.9)

1.000

 Overall implanted devices

124

(59)

121

(57)

0.768

Medication at discharge, n (%)

Beta-blocker

162

(76)

187

(88)

0.001

 ACE-inhibitor

115

(54)

153

(72)

0.001

 AT1-Antagonist

21

(10)

29

(14)

0.249

 Aldosteron-antagonist

22

(10)

33

(16)

0.112

 Aspirin only

58

(27)

78

(37)

0.037

 Thienopyridine only

4

(2)

10

(5)

0.103

 Dual antiplatelet therapy

25

(12)

52

(25)

0.001

 Vitamin k antagonist

54

(26)

48

(23)

0.495

 NOAC

7

(3)

2

(0.9)

0.175

 Amiodarone

54

(26)

38

(18)

0.059

 Digitalis

33

(16)

38

(18)

0.515

Hospitalization time, days, (median (IQR))

 Total hospitalization time

16 (8–27)

14 (8–26)

0.009

 ICU time

3 (0–11)

2 (0–7)

0.004

 Follow-up time, days, (mean; median (range))

1849; 1806

(25–5095)

1853; 1675

(18–5091)

0.013

All cause-mortality at 3 years, n (%)

70

(33)

33

(16)

0.001

  1. CABG; coronary artery bypass grafting; CAD, coronary artery disease; CRT-D, cardiac resynchronization therapy plus defibrillator; CRT-P, cardiac resynchronization therapy plus pacemaker; CTO, chronic total occlusion; LAD, left anterior descending; LCX, left circumflex; LVEF, left ventricular ejection function; ICD, implantable cardioverter-defibrillator; ICU, intensive care unit; IQR, interquartile range; NOAC, new oral anticoagulants; PCI, percutaneous coronary intervention; RCA, right coronary artery; RIM, Ramus intermedius. Bold type indicates p < 0.05